234 related articles for article (PubMed ID: 30017201)
1. Anti-EGFR antibody cetuximab is secreted by oral squamous cell carcinoma and alters EGF-driven mesenchymal transition.
Fujiwara T; Eguchi T; Sogawa C; Ono K; Murakami J; Ibaragi S; Asaumi JI; Okamoto K; Calderwood SK; Kozaki KI
Biochem Biophys Res Commun; 2018 Sep; 503(3):1267-1272. PubMed ID: 30017201
[TBL] [Abstract][Full Text] [Related]
2. Carcinogenic epithelial-mesenchymal transition initiated by oral cancer exosomes is inhibited by anti-EGFR antibody cetuximab.
Fujiwara T; Eguchi T; Sogawa C; Ono K; Murakami J; Ibaragi S; Asaumi JI; Calderwood SK; Okamoto K; Kozaki KI
Oral Oncol; 2018 Nov; 86():251-257. PubMed ID: 30409309
[TBL] [Abstract][Full Text] [Related]
3. Epidermal Growth Factor (EGF) Autocrine Activation of Human Platelets Promotes EGF Receptor-Dependent Oral Squamous Cell Carcinoma Invasion, Migration, and Epithelial Mesenchymal Transition.
Chen R; Jin G; Li W; McIntyre TM
J Immunol; 2018 Oct; 201(7):2154-2164. PubMed ID: 30150285
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor/epidermal growth factor receptor signaling blockage inhibits tumor cell-derived exosome uptake by oral squamous cell carcinoma through macropinocytosis.
Sasabe E; Tomomura A; Liu H; Sento S; Kitamura N; Yamamoto T
Cancer Sci; 2022 Feb; 113(2):609-621. PubMed ID: 34874595
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of epithelial-mesenchymal transition by cetuximab via the EGFR-GEP100-Arf6-AMAP1 pathway in head and neck cancer.
Matsumoto Y; Sakurai H; Kogashiwa Y; Kimura T; Matsumoto Y; Shionome T; Asano M; Saito K; Kohno N
Head Neck; 2017 Mar; 39(3):476-485. PubMed ID: 27880014
[TBL] [Abstract][Full Text] [Related]
6. Eribulin sensitizes oral squamous cell carcinoma cells to cetuximab via induction of mesenchymal-to-epithelial transition.
Kitahara H; Hirai M; Kato K; Bou-Gharios G; Nakamura H; Kawashiri S
Oncol Rep; 2016 Dec; 36(6):3139-3144. PubMed ID: 27779690
[TBL] [Abstract][Full Text] [Related]
7. Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer.
Keysar SB; Le PN; Anderson RT; Morton JJ; Bowles DW; Paylor JJ; Vogler BW; Thorburn J; Fernandez P; Glogowska MJ; Takimoto SM; Sehrt DB; Gan GN; Eagles-Soukup JR; Serracino H; Hirsch FR; Lucia MS; Thorburn A; Song JI; Wang XJ; Jimeno A
Cancer Res; 2013 Jun; 73(11):3381-92. PubMed ID: 23576557
[TBL] [Abstract][Full Text] [Related]
8. EGF induces epithelial-mesenchymal transition and cancer stem-like cell properties in human oral cancer cells via promoting Warburg effect.
Xu Q; Zhang Q; Ishida Y; Hajjar S; Tang X; Shi H; Dang CV; Le AD
Oncotarget; 2017 Feb; 8(6):9557-9571. PubMed ID: 27926487
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor is a potential biomarker for poor cetuximab response in tongue cancer cells.
Ansell A; Jedlinski A; Johansson AC; Roberg K
J Oral Pathol Med; 2016 Jan; 45(1):9-16. PubMed ID: 25677871
[TBL] [Abstract][Full Text] [Related]
10. Combination of NTP with cetuximab inhibited invasion/migration of cetuximab-resistant OSCC cells: Involvement of NF-κB signaling.
Chang JW; Kang SU; Shin YS; Seo SJ; Kim YS; Yang SS; Lee JS; Moon E; Lee K; Kim CH
Sci Rep; 2015 Dec; 5():18208. PubMed ID: 26655729
[TBL] [Abstract][Full Text] [Related]
11. A potential link between desmoglein 3 and epidermal growth factor receptor in oral squamous cell carcinoma and its effect on cetuximab treatment efficacy.
Minabe M; Akiyama Y; Higa K; Tachikawa T; Takahashi S; Nomura T; Kouno M
Exp Dermatol; 2019 May; 28(5):614-617. PubMed ID: 30907457
[TBL] [Abstract][Full Text] [Related]
12. Hsa_circ_0005379 regulates malignant behavior of oral squamous cell carcinoma through the EGFR pathway.
Su W; Wang Y; Wang F; Sun S; Li M; Shen Y; Yang H
BMC Cancer; 2019 Apr; 19(1):400. PubMed ID: 31035951
[TBL] [Abstract][Full Text] [Related]
13. Resistance of oral squamous cell carcinoma cells to cetuximab is associated with EGFR insensitivity and enhanced stem cell-like potency.
Ohnishi Y; Minamino Y; Kakudo K; Nozaki M
Oncol Rep; 2014 Aug; 32(2):780-6. PubMed ID: 24926885
[TBL] [Abstract][Full Text] [Related]
14. Cetuximab inhibits oral squamous cell carcinoma invasion and metastasis via degradation of epidermal growth factor receptor.
Dai W; Li Y; Zhou Q; Xu Z; Sun C; Tan X; Lu L
J Oral Pathol Med; 2014 Apr; 43(4):250-7. PubMed ID: 24020947
[TBL] [Abstract][Full Text] [Related]
15. Design of an EGFR-targeting toxin for photochemical delivery: in vitro and in vivo selectivity and efficacy.
Berstad MB; Cheung LH; Berg K; Peng Q; Fremstedal AS; Patzke S; Rosenblum MG; Weyergang A
Oncogene; 2015 Oct; 34(44):5582-92. PubMed ID: 25684137
[TBL] [Abstract][Full Text] [Related]
16. The hypoxic tumor microenvironment and drug resistance against EGFR inhibitors: preclinical study in cetuximab-sensitive head and neck squamous cell carcinoma cell lines.
Boeckx C; Van den Bossche J; De Pauw I; Peeters M; Lardon F; Baay M; Wouters A
BMC Res Notes; 2015 Jun; 8():203. PubMed ID: 26032726
[TBL] [Abstract][Full Text] [Related]
17. Decreased SMAD4 expression is associated with induction of epithelial-to-mesenchymal transition and cetuximab resistance in head and neck squamous cell carcinoma.
Cheng H; Fertig EJ; Ozawa H; Hatakeyama H; Howard JD; Perez J; Considine M; Thakar M; Ranaweera R; Krigsfeld G; Chung CH
Cancer Biol Ther; 2015; 16(8):1252-8. PubMed ID: 26046389
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical localization of epidermal growth factor (EGF) and EGF receptor in human oral mucosa and its malignancy.
Shirasuna K; Hayashido Y; Sugiyama M; Yoshioka H; Matsuya T
Virchows Arch A Pathol Anat Histopathol; 1991; 418(4):349-53. PubMed ID: 2024456
[TBL] [Abstract][Full Text] [Related]
19. EGFR-mediated signaling pathway influences the sensitivity of oral squamous cell carcinoma to JQ1.
Liu X; Li Q; Huang P; Tong D; Wu H; Zhang F
J Cell Biochem; 2018 Oct; 119(10):8368-8377. PubMed ID: 30687956
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of BMP signaling overcomes acquired resistance to cetuximab in oral squamous cell carcinomas.
Yin J; Jung JE; Choi SI; Kim SS; Oh YT; Kim TH; Choi E; Lee SJ; Kim H; Kim EO; Lee YS; Chang HJ; Park JY; Kim Y; Yun T; Heo K; Kim YJ; Kim H; Kim YH; Park JB; Choi SW
Cancer Lett; 2018 Feb; 414():181-189. PubMed ID: 29154973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
